MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
01 Agosto 2023 - 9:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the
signing of a strategic partnership with Prime Medicine, Inc., a
biotechnology company committed to delivering a new class of
differentiated one-time curative genetic therapies.
Under the terms of the agreement, Prime Medicine obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive annual license fees and
program-related revenue.
“We are pleased to partner with Prime Medicine and support their
breakthrough gene editing technology,” said Doug Doerfler,
President and CEO of MaxCyte. “The company’s innovative
vision and transformative scientific approach are clearly reshaping
how genetic diseases are studied and ultimately will be
treated.”
Prime Medicine is a leading biotechnology company dedicated to
creating and delivering the next generation of gene editing
therapies to patients. The Company is leveraging its proprietary
Prime Editing platform, a versatile, precise and efficient gene
editing technology, to develop a new class of differentiated,
one-time, potentially curative genetic therapies. Designed to make
only the right edit at the right position within a gene while
minimizing unwanted DNA modifications, Prime Editors have the
potential to repair almost all types of genetic mutations and work
in many different tissues, organs and cell types.
MaxCyte’s ExPERT™ instrument portfolio is the next generation of
leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability, and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Prime Medicine is MaxCyte’s 23rd strategic
partnership overall, each of which generates pre-commercial
milestone revenue and the vast majority of which include
sales-based payments.
About MaxCyte At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients’ lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today’s
processes to innovate tomorrow’s solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT™ family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR Adviser Gilmartin
Group David Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media Relations Spectrum
Seismic Collaborative Valerie Enes +1
408-497-8568 valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure Gordon Emma Earl / Freddy
Crossley Corporate Broking Rupert Dearden +44 (0)20
7886 2500
UK IR Adviser Consilium Strategic
Communications Mary-Jane Elliott Chris
Welsh +44 (0)203 709 5700 maxcyte@consilium-comms.com
Maxcyte (LSE:MXCT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Maxcyte (LSE:MXCT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024